



BEST AVAILABLE COPY

REMARKS

Applicants amend claim 38 herein to correct an error in such claim. Specifically, while reviewing the subject application in preparation for payment of the issue fee Applicants noted that two species in claim 38 are outside of the allowed subject matter. That is, (i) the first deleted species of claim 38 : N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-(5-[[2-(methylsulfonyl)ethoxy]methyl]-2-furyl)-4-quinazolinamine has an R<sup>5</sup> group which is an unsubstituted C<sub>1-6</sub> alkyl ( R<sup>5</sup> is limited in claim 1 to substituted C<sub>1-6</sub> alkyl); and (ii) the second deleted species of claim 38 : N-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-(5-[[2-(vinylsulfonyl)ethoxy]methyl]-2-furyl)-4-quinazolinamine has an R<sup>5</sup> group which is a C<sub>2-4</sub> alkenyl ( R<sup>5</sup> does not list in claim 1 C<sub>2-4</sub> alkenyl within its scope).

Applicants note that the proposed Section 312 amendment does not introduce new matter into the claims nor raise new issues for prosecution. Rather, the amendment merely corrects an error in the claims. Applicants respectfully requests entry of the subject Section 312 amendment.


**BEST AVAILABLE COPY**



**CONCLUSION**

The points and concerns of the Examiner having been addressed in full, Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. Should any issues remain unresolved in this application which would bar issuance the Examiner is invited to contact the undersigned Attorney at (919) 483-8247, to discuss such issues. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

  
John L. Lemanowicz  
Attorney for Applicants  
Registration No. 37,380

Date: 10 February, 2005  
Glaxo Smith Kline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, North Carolina 27709  
(919) 483-8247